EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinie

Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use

Garshasb P Soroosh, Erfan Tasdighi, Rishav Adhikari, Michael J Blaha

Progress in Cardiovascular Diseases · 2024

DOI: 10.1016/j.pcad.2024.05.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2024. Verfasst von Garshasb P Soroosh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electro…. Hauptthemen laut MEDLINE: Coronary Artery Disease, Vascular Calcification, Aspirin, Cholesterol, LDL. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Personalizing risk assessment and treatment decisions for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) rely on pooled cohort equations and increasingly coronary artery calcium (CAC) score. A growing body of evidence supports that elevated CAC scores correspond to progressively elevated ASCVD risk, and that scores of ≥100, ≥300, and ≥1000 denote risk that is equivalent to certain secondary prevention populations. This has led consensus guidelines to incorporate CAC score thresholds for guiding escalation of preventive therapy for lowering low-density lipoprotein cholesterol goals, initiation of non-statin lipid lowering medications, and use of low-dose daily aspirin. As data on CAC continues to grow, more decision pathways will incorporate CAC score cutoffs to guide management of blood pressure and cardiometabolic medications. CAC score is also being used to enrich clinical trial study populations for elevated ASCVD risk, and to screen for subclinical coronary atherosclerosis in patients who received chest imaging for other diagnostic purposes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseVascular CalcificationAspirinCholesterol, LDLBiomarkersPractice Guidelines as TopicHumansRisk AssessmentPlatelet Aggregation InhibitorsTreatment OutcomePrimary PreventionDyslipidemiasRisk FactorsPredictive Value of TestsCoronary Vessels

Stichwörter der Autor:innen

ASCVDAspirin.CACLipid-lowering therapy.Personalized medicine.

Substanzen

AspirinCholesterol, LDLBiomarkersPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: gsoroos1@jhmi.edu.
  • Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

Förderung

  • National Institutes of Health

Zitieren

APA

Soroosh, G. P., Tasdighi, E., Adhikari, R., & Blaha, M. J. (2024). Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2024.05.004

Vancouver

Soroosh GP, Tasdighi E, Adhikari R, Blaha MJ. Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use. Progress in Cardiovascular Diseases. 2024. doi:10.1016/j.pcad.2024.05.004

BibTeX
@article{Soroosh2024,
  author = {Soroosh, Garshasb P and Tasdighi, Erfan and Adhikari, Rishav and Blaha, Michael J},
  title = {Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use},
  journal = {Progress in Cardiovascular Diseases},
  year = {2024},
  doi = {10.1016/j.pcad.2024.05.004}
}
Kostenlos starten →